Drug Profile
Research programme: calgranulin B inhibitors - Active Biotech
Alternative Names: Inhibition of S100A9 Interactions; ISI; S100A9 Inhibition by Low molecular weight Compounds; SILCLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Active Biotech
- Developer Active Biotech; Erasmus MC
- Class Antineoplastics; Quinolines; Small molecules
- Mechanism of Action Calgranulin B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Myelofibrosis
- No development reported Cancer
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cancer in Sweden
- 09 Feb 2022 Oncode Institute, Active Biotech and Erasmus MC signs a patent licensing agreement for tasquinimod in Myelofibrosis
- 09 Feb 2022 Early research in Myelofibrosis in Netherlands (unspecified route)